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Abstract
Bisphenol A (BPA), an endocrine disruptor involved in synthesizing numerous 
types of plastics, is detected in almost the entire population’s urine. The present 
work aims to estimate daily exposure to BPA by systematically reviewing all articles 
with original data related to urinary BPA concentration. This approach is based on 
human pharmacokinetic models, which have shown that 100% of BPA (free and 
metabolized form) is eliminated only in a few hours through urine. Several exten-
sive population studies and experimental data have recently proven a significant 
association between urinary excretion of BPA and albuminuria, associated with 
renal damage. Our team’s previous work has shown that low-dose BPA can promote 
a cytotoxic effect on renal mouse podocytes. Moreover, BPA administration in mice 
promotes kidney damage and hypertension. Furthermore, preliminary studies 
in human renal cells in culture (podocytes) strongly suggest that BPA might also 
promote kidney damage. Overall, the present review analyzed BPA exposure data 
from mammalian cell studies, experimental animal models, and several human 
populations. Studying principal cohorts calculated the exposures to BPA globally, 
showing a high BPA exposure suggesting the need to decrease BPA exposure more 
effectively, emphasizing groups with higher sensitivity as kidney disease patients.
Keywords: bisphenol A, systematic review, human, urine, estimated daily intake
1. Introduction: brief historical overview
Bisphenol A is the perfect example of the double edge of industrial develop-
ment. On the one hand, thanks to BPA, we have countless plastic objects with 
excellent physical properties at low prices; on the other hand, increasing exposure 




BPA is a phenolic compound widely distributed due to its multiple uses as an 
additive and plasticizer in plastic polymers’ manufacture [1]. This compound can 
be found in various everyday items, such as food containers, toys, dental supplies, 
electronic devices, and even clothing [2–6].
The BPA problem presents a particular and curious situation: BPA is a compound 
whose properties as an estrogen modulator were already determined 84 years ago by 
medical researchers at the University of London [7], but its use increased substan-
tially last decades. The discoverer’s idea was to commercialize a compound that could 
treat female pathologies. Finally, they succeeded with Diethylstilbestrol, a substance 
with much greater potency than BPA, and was introduced in the 1940s [8].
It took about 50 years since the Russian chemist Dianin synthesized it in 1891 
[9, 10] until the BPA began to be used in the industrial manufacturing of epoxy 
resins. Still, due to its incredible versatility, BPA quickly achieved great importance 
in the American industry. In the mid-1970s, the BPA was considered a part, directly 
or indirectly, of all major US industries [8]. In parallel, Schnell’s contributions in 
1956 demonstrated BPA’s potential role in producing polycarbonates [11, 12]. Due 
to its unique combination of physical properties, this type of compound has had a 
significant impact on the world industry, as have epoxy resins. Today they are still 
used in numerous applications, such as in the automotive or LED sector [12]. In 
fact, there is a tendency to increase its consumption in the coming years, as can be 
seen in the Asian market, where there has been a substantial increase in the demand 
for polycarbonates in the last ten years [13]. It is expected to continue growing in 
the years to come, as observed in the American market [14].
2.  Novel role of BPA in renal, cardiovascular and hypertensive diseases; 
latest discoveries
2.1 BPA in the renal system
BPA is a compound widely studied for its estrogenic properties within the field 
of fertility and sexual organs. However, other organs, such as the kidney and liver, 
may have the highest exposure ranges. In the kidney’s case, BPA concentration 
has been positively correlated with a greater predisposition to kidney pathologies 
[15–17] or clinical signs associated with kidney diseases, such as increased albumin-
uria or decreased glomerular filtration rate [18–21].
Our group has worked on BPA’s possible action on the renal system in recent 
years, using different cell and animal models. The first steps were carried out on 
a renal cell line of immortalized mouse podocytes. It was possible to observe how 
the chronic treatment of BPA exerts a cytotoxic effect on the cells. The admin-
istration of 10 and 100 nM doses for nine days exerted loss of cell viability and 
increased apoptosis (as assessed by MTT and TUNEL, respectively). These effects 
were accompanied by an increase in the synthesis of molecules classically involved 
in the pathogenesis of glomerulosclerosis, such as the cyclin-dependent kinase 
inhibitor p27kip1, the TGF-β system, and collagen IV. Furthermore, in these cells, 
BPA reduced the synthesis of nephrin and podocin, proteins of the filtration slits 
involved in proteinuria and podocyte survival mechanisms. As would be expected 
from these in vitro results, the kidneys of animals treated with BPA developed 
hypertrophy, hyperfiltration, and proteinuria. Along with the increased renal 
expression of p27kip1, TGF-β, and collagen IV, mesangial expansion and a decrease 
in the number of podocytes due to apoptosis were also seen. Electron microscopy 
showed hypertrophy of podocytes and pedicles. It should be noted that even when 
animals treated with BPA did not develop hyperglycaemia, their kidneys showed 
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structural and functional changes similar to those that occur in the initial stages of 
diabetic nephropathy (DN) (Figure 1) [22, 23].
Secondly, the possible effects of BPA on an immortalized human podocyte cell 
line were explored. We observed that BPA promotes a novel type of podocytopathy 
characterized by an impairment of cell adhesion by altering adhesion and cytoskel-
eton proteins’ expression.
By using transcriptomics, proteomics, western-blot, and immunocytochem-
istry, it was possible to determine that BPA at low doses promotes a reduction 
in the expression of numerous structural or adhesion proteins, such as tubulin, 
vimentin, podocin, cofilin-1, vinculin, E-cadherin, nephrin, and VCAM-1, as well 
as an increase in the expression of proteins that negatively participate in adhesion 
mechanisms, such as Tenascin-C [24].
Since podocytes do not replicate in adults, the resulting podocytopenia after the 
urinary loss of podocytes might promote glomerulosclerosis. Collectively all available 
data suggest that BPA could participate in the pathogenesis and progression of renal 
diseases. It is essential to mention that these experimental results are supported by 
epidemiological studies conducted in the populations of New York [25], Shanghai [19], 
Figure 1. 
Notable evidence from cell and animal models. A) TUNEL technique performed in mouse podocytes. Note the 
significant increase in the number of apoptotic cells in the cells treated with BPA. B) Hypertensive effect of 
BPA administered to animals in drinking water. C) Reduction in the number of glomerular podocytes (labelled 
with WT-1) of the mice treated with intraperitoneal (IP) BPA. D) Increased number of apoptotic kidney cells 
(TUNEL) of mice treated with IP BPA. E) Adhesion assay in human podocytes. A reduction of up to 50% was 
observed in cells treated with BPA. F) Podocin immunocytochemistry in human podocytes. A significant loss of 
labelling is evidenced in cells treated with BPA. * or @ means p-value < 0,05; ** or @@ means p < 0,01; *** or 
@@@ means p < 0,001; **** or @@@@ means p < 0,0001. Figure made with our own results published in the 
Journal of Cellular Physiology [22], FASEB Journal [27] and Scientific Reports [24].
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and Seoul [26], which describe an association between human exposure to BPA and an 
increase in proteinuria and hypertension.
2.2 BPA in the cardiovascular system
Further studies demonstrated that animals treated with BPA developed arterial 
hypertension and endothelial dysfunction in a dose-dependent manner (Figure 1). 
Microarray analysis of gene expression in murine endothelial cells treated with BPA 
demonstrated the activation of genes involved in vascular regulation, such as angio-
tensin II and calcium-calmodulin kinase II (CaMKII). This event was subsequently 
observed in vivo as well. The activation is responsible for the endothelial dysfunc-
tion and hypertension induced by BPA, given that CaMKII activation promotes the 
enzymatic uncoupling of endothelial nitric oxide synthase. This phenomenon leads 
to oxygen free radicals’ production instead of nitric oxide, a primary vasodilator, 
and endothelial protector. Moreover, this increased production of oxygen free radi-
cals indicates that BPA, and inducing hypertension, could participate in vascular 
damage mechanisms and atherosclerotic lesions’ progression [23, 27]. Besides, 
recent data demonstrated the cardiotoxic effect of BPA by a mechanism that 
involved activation of the RIP 3-CamKII necroptotic pathway leading to endothelial 
cell death. Decreased endothelial barrier function and weakening of the coronary 
vascular wall in the setting of hypertension may cause ventricular hemorrhages, 
cardiac and lung congestion, which ultimately led to heart failure [28].
3.  BPA exposure in the general population. Identification of groups with 
higher exposure
3.1 Pharmacokinetics of BPA
The heterogeneous distribution of BPA results in the ability to enter the body 
in multiple ways. The main entry route is considered oral, through the ingestion 
of food or beverages containing BPA [29, 30]. However, there are other routes like 
inhalation (air or dust) [31–34], dermal (cosmetics, thermal tickets) [35–37], and it 
has even been hypothesized with the ocular [38] and sublingual routes [35, 39]. It is 
estimated that between 85 and 100% of the BPA ingested can be absorbed through 
the intestine. Thanks to its capacity to cross biological barriers, it has been observed 
that BPA has the potential to distribute itself through any fluid and biological tis-
sue, even crossing the transplacental or blood–brain barrier [29, 40, 41]. In the case 
of the dermal route, it has been determined that the ability of BPA to enter the body 
is lower, with percentages less than 10% [42, 43]. For its part, the sublingual route 
(of great importance in the elements used in dentistry) seems that it could become 
more efficient than the intestinal entry [39].
BPA’s metabolism is marked by phase II reactions, biochemical mechanisms 
capable of modifying its structure to facilitate its excretion [44]. BPA is metabo-
lized towards glucuronidation or sulfonation in the intestine and the liver  
[41, 45, 46], but the metabolic capacity can be seriously reduced in diseases such 
as obesity or diabetes [47]. Glucuronidation is the majority reaction, mediated 
by uridine diphosphate glucuronosyltransferase (UGT) [44, 48]. It has also been 
suggested that a part of the BPA that reaches the intestine could be degraded to 
p-cresol by the intestinal microbiota, thus generating uremic toxins [49]. Another 
possible route studied has been hydroxylation to catechol, followed by a trans-
formation to o-quinone. This route, like the previous one, can generate toxicity 
associated with oxidative stress [50].
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Pharmacokinetic studies in rodents have determined that BPA is excreted in 
urine and feces [29, 51, 52]. It has been observed that BPA is excreted exclusively 
through the urine in non-human primates and humans [41, 53, 54]. This phenom-
enon makes it much easier to make a rough estimate of the degree of exposure by 
BPA’s urinary quantification. The inter-species differences observed are attributed 
to a possible higher enterohepatic recirculation in rodents [29, 51, 52]. However, 
there is evidence that contradicts this hypothesis [55].
3.2 Calculation of BPA exposure in the general population
As mentioned above, thanks to pharmacokinetic studies in humans [41, 53, 54], 
it is accepted that 100% of BPA is eliminated via the urinary tract, which can be 
used to determine the degree of daily exposure to this compound quickly. For this 
reason, we proceed to evaluate the question of the degree of global exposure through 
a systematic review of principal cohorts in the world. To estimate human exposure 
to BPA, we first collected data published by one of the world’s largest cohorts: the 
National Health and Nutrition Examination Survey (NHANES). NHANES is a 
survey research program conducted by the US National Center for Health Statistics 
(NCHS), with more than 72,000 patients studied between 2003 and 2016 [56].
After extracting all the data and unifying them, 18,244 urinary BPA concentra-
tions were obtained. A non-parametric distribution was obtained after performing 
Continent N Population group (cohort / city) GM
America 18,244 General population [Own study*] 1.77
Asia 6,003 General Population (KoNEHS) [61] 1.13
America 5,476 General Population (CHMS) [62] 1.6
Asia 3,455 General Population (Shanghai) [63] 0.82
Asia 2,535 Pregnant (Wuhan) [64] 0.9
America 2,477 General Population (Ex-R study) [65] 1.96
America 2,318 General Population (HOPE) [66] 2.52
Asia 2,044 General Population (KRIEFS) [67] 1.83
Europe 1,996 Pregnant (SELMA) [68] 1.53
America 1,933 Pregnant (MIREC) [69] 0.9
America 1,868 Pregnant (PROTECT) [70] 2.02
Europe 1,764 Pregnant (Elfe) [71] 0.69
Asia 1,625 General Population (KEEP) [72] 0.71
America 1,543 Pregnant (LifeCodes) [73] 1.18
Europe 1,396 Pregnant (Generation R) [74] 1.68
Europe 1,146 General Population (DESIR) [75] 1.78
Europe 1,084 Pregnant (HELIX) [58] 3.38
Oceania 420 General Population (Brisbane) [76] 2.61
Africa 210 General Population (Giza) [77] 0.68
Note that two results have been included with a reduced sample size to include Oceania and Africa. Meaning of 
abbreviations: K, kids; A, adults; GM, geometric mean (or corrected median).
*Own study corresponds with NHANES 2003 – 2016 cohort.
Table 1. 
Representative data from the main cohorts in the world.
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the normality tests, for which the geometric mean (GM) was calculated, obtaining 
a result of 1.77 ng/ml. A systematic review of urinary BPA was then carried out to 
select from among all the publications with the most representative cohorts from 
each continent and the largest number of people. Using the keywords: Bisphenol 
AND (urine OR urinary) in the reference search engines Pubmed and Web of 
Science, a total of 999 and 2,025 results were obtained, respectively. Once the 
duplicates were eliminated, a total of 2,414 publications remained. After screening 
by title/abstract, a total of 756 publications were selected. Finally, after reading 
in-depth, 447 articles were selected whose pages describe urinary concentrations 
of BPA in some population groups, either general or specific, such as patients 
with various pathologies, pregnant women, the elderly, or workers subjected to 
occupational exposure. All data from the 447 academic articles were collected and 
analyzed carefully. According to the country, population group, and sample size, 
the primary world cohorts were selected from all of them, obtaining 16 cohorts 
whose sample sizes exceed 1000 individuals from America, Asia, and Europe 
(Table 1). A result of Oceania and another from Australia was also included due to 
representability. All of them expressed the concentration of BPA in ng/ml except 
one of them, which expressed it in μg per gram of creatinine (μg/g creat.) [57]. 
Therefore, it was modified by calculating the average creatinine concentration in 
adults using the NHANES cohort’s data and the other two major cohorts, KoNEHS 
and CHMS [58, 59].
We consider that in the study of urinary BPA, where the results follow non-
parametric distributions, the values that should be analyzed would correspond 
to the GM or the median. To determine if both values can be unified, they were 
examined using linear regression, observing that they were always in the same 
range, and the variation between them was relatively small. The equation of a line 
was Y = 0.9855 * X, and R2 = 0.9919. For this reason, the decision was reached to 




































































































Meaning of abbreviations: Gen.Pop., General population; Oc.Exp., Occupational Exposure.
Table 2. 
Higher urinary BPA values determined according to the geometric mean (GM), median, 95th percentile (P95), 
or maximum value (MAX).
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use the GM, preferably, but if it was not recorded, use the median corrected with 
the equation obtained.
Next, the urinary BPA was averaged, considering each cohort’s sample size, 
obtaining a final result of 1.55 ng/ml (with a sample size of 57,537 individuals). 
Once the average concentration determined in the general population’s urine has 
been established, the next step will be carried out on the highest values found in the 
systematic review to determine interest groups to study BPA exposure.
As reflected in Table 2, it is clear that workers subjected to occupational expo-
sure are the ones who are likely to find a more significant entry of BPA into their 
bodies. The highest values observed, both of the median and the maximum value 
(MAX), correspond entirely to people subjected to occupational exposure, such as 
workers in the plastics industry. The highest GM value stands out, as it corresponds 
to the general Iranian population. An in-depth study would be necessary to be 
able to discern the problem that underlies this study area. Interestingly, unusually 
high 95th percentile values can also be seen in pregnant women and intensive care 
patients. It is likely that consumable medical supplies, such as catheters or hemodia-
lyzers, could increase BPA exposure due to their plastic composition. Bearing this in 
mind, and in keeping with the discoveries described in basic research, the study and 
analysis of BPA exposure in patients undergoing hemodialysis is crucial.
4. Systematic review of BPA exposure in hemodialysis patients
After describing the latest advances in the BPA-kidney paradigm investigation, 
the need to include kidney patients as a group of special vulnerability to exposure 
to BPA is evident. Thereof, there is a point of convergence in the final stages within 
the different pathologies or stages: the need for dialysis due to the kidney’s reduced 
functionality. Interestingly, there is evidence that the use of surgical medical equip-
ment can increase exposure to compounds such as BPA due to the composition of its 
materials. Therefore, we will analyze the urinary concentration of BPA in patients 
undergoing hemodialysis procedures to estimate the daily exposure to which they 
are subjected. The systematic review methodology was used again, using the 
keywords: bisphenol AND (dialysis OR hemodialyzer OR hemodiafiltration OR 
hemodialysis OR dialyzer).
Thirty-eight results were obtained in Pubmed and 50 in Web of Science. After 
eliminating duplicates, a total of 66 documents were obtained. Once the first 
screening by title/abstract was done to look for BPA concentrations in patients 
undergoing hemodialysis, a total of 20 publications were accepted. After carefully 
studying the text, ten publications were selected1. Of these, only 1 quantifies the 
urinary BPA concentration in dialysis patients [60] and 9 in serum [15, 60–68].
The publication by Schöringhumer et al., which quantifies urinary BPA, obtains 
concentrations between 0.4 and 2.6 ng/ml within the same range as the general 
population [60], equivalent to 1.75–11.39 nM. In general terms, low exposure would 
be considered. Still, considering the in vitro model results and the patient’s pathol-
ogy, it could pose an added risk for kidney disease evolution. In the case of publica-
tions that study BPA in serum, some show values similar to those observed in the 
general population’s urine. Among them, we can find the publications of Kanno et al. 
(5.3 ± 0.3 ng/ml), Murakami et al. (values between 1.48 ± 1.41 and 6.62 ± 3.09), 
Sajiki et al. (values between 0.179 ± 0.263 and 0.642 ± 1.443), Shen et al. (1.01) or 
Turgut et al. (5.57 ± 1.2) [61, 64, 66–68]. Higher values have the publications of 
Quiroga et al. (high flux hemodialysis: 7.5 ± 3.5; online hemodiafiltration: 6.7 ± 2.5) 
1 Those publications without relevant data, reviews, and conference communications were discarded.
Endocrine Disruptors
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and Krieter et al. (10 ± 6.6) [15, 65]. Finally, Bosch-Panadero et al. and Mas et al. 
describe serum BPA values in patients undergoing conventional dialysis that range 
from 52.73 ± 60.6 to 163.03 ± 155.84. Also, they quantify serum BPA concentrations 
in patients undergoing online hemodiafiltration from 8.79 ± 7.97 to 23.42 ± 20.38) 
[62, 63]. These high values would be equivalent to 230.98–714.14 nM in the case of 
conventional dialysis and 38.50–102.59 nM in online hemodiafiltration.
5. Systematic review of occupational exposure to BPA
The alarming data described in the previous pages denote the need to study 
occupational exposure. To this end, we proceeded to use two academic reference 
search engines, Pubmed and Web of Science, using the following keywords: 
Bisphenol AND (workers OR occupational exposure OR exposure workplace), 
obtaining a total of 658 publications (once repeated results were eliminated). Of 
all of them, 25 publications were adapted to the search. Only publications with 
urinary BPA (or blood) concentrations were selected in workers with high expo-
sure or themselves before and after their work shift. Of the 25 studies selected for 
their affinity with the topic of interest, we can distinguish three subgroups: In the 
first (G1)2, BPA concentrations can be observed well above the average, and with 
significant differences between the study groups. In the second group (G2)3, there 
are concentrations higher than the mean in a range closer to it, while in the third 
group (G3), the range of concentrations is within the range of values of the general 
population.
5.1 G1: extremely high BPA concentrations
From a quantitative perspective, within G1, the most interesting publication 
is Liu et al. [69]. It compares BPA concentrations in people with potential occu-
pational exposure versus controls, obtaining substantially different values. The 
median values (interquartile range, IR) between exposed workers vs. controls are 
685.9 (43.7–3671.8) vs. 4.2 (0–15.9) μg/g creat. Other equally interesting values are 
Tian et al. [70] and Song et al. [71]. Firstly, they determine geometric mean (GM) 
values (standard deviation, SD) between exposed subjects vs. control of 158.41 
(17.92) vs. 0.84 (6.53) μg/g creat., reaching in the second publication, the values 
of 199.13 (19.65) vs. 0.77 (6.33) μg/g creat. Song et al.’s publication determine the 
highest maximum urinary BPA concentration, reaching the value of 264,219.38 μg/g 
creat., (264.22 mg/g creat.).
The next publications to consider are two by Hines et al. [72, 73], where they 
study exposure to BPA in different factories before and after the work shift. In 
them, essential differences can be appreciated, showing, to cite an example of each 
article, a GM (SD) in pre-shift vs. post-shift of 6.2 (4.3) vs. 130 (10) μg/sample or 
26.6 (5.74) vs. 178 (6.2) μg/g creat. These groups show arithmetic mean (SD) values 
of 15 (22) vs. 2300 (5800) μg/sample and 115 (252) vs. 812 (2330) μg/g creat. The 
maximum BPA value is also very striking, reaching 32,900 ng/ml. We will continue 
with the study of publications with high BPA values, Xiao et al. [74], and the two 
publications by Li et al. [75, 76]. They show differences between exposed workers 
vs. control, showing medians of 101.94 vs. 0 ng/ml of serum in the first case and 
2 All those publications with geometric means or medians greater than 50 (ng/ml, μg/g creat., μg/urine 
sample, or ng/ml of plasma) have been selected.
3 We have selected those publications with values of geometric means/medians lower than 50 and higher 
than 8 (at least four times above the global mean).
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57.9 vs. 1.2 and 53.7 vs. 1.2 μg/g in the other two. Finally, it is important to mention 
the works of He et al. [77] and Wang et al. [78]. In the first, they find pre-shift vs. 
post-shift differences of 84.6 vs. 111 μg/g creat. (median) and 4630 vs. 5400 μg/g 
creat. (AM). In the second publication, they quantify urinary BPA concentrations 
in workers of an epoxy resin factory, with a GM (SD) of 55.73 (5.48) and a maxi-
mum value of 1934.85 ng/ml.
5.2 G2: elevated BPA concentrations
Within G2, where the concentrations are not so high, articles such as those by Li 
et al. [79] or Miao et al. [80, 81]. In them, differences between exposed vs. control 
are determined, observing medians (IR) of 38.7 (6.3–354.3) vs. 1.4 (0.0–17.9) μg/g 
creat. in the first case, AM (SD) of 36.23 (7.69) vs. 1.38 (6.89) μg/g creat. in the 
second, and GM (95% confidence interval, CI) of 22.2 (12.4–39.8) vs. 0.9 (0.7–1.1) 
μg/g creat. in the latter. The same pattern can be observed in the work of Ndaw et al.  
[82], where higher values are observed in cashiers exposed to thermal tickets vs. 
controls, determining a GM (SD) of 8.58 (2.83) vs. 3.52 (2.35). For their part, 
Zhuang et al. [83] carried out a slightly different approach since they determined 
differences between workers of an epoxy resin company with a working time 
greater than five years versus those in the company for less than five years. The 
median values observed reflected a significant increase in workers with a longer 
working time (27.18 vs. 9.73 ng/ml serum). Finally, the work of Heinälä et al. [84] is 
also included in this group, where the pre-shift vs. post-shift urinary concentration 
is studied, quantitatively highlighting the GM of the heat-sensitive paper producing 
company, 18.7 vs. 39.4 ng/ml, or from the liquid paint producer, 4.6 vs. 10.3 ng/ml 
of urine.
5.3 G3: “normal” range but with significant differences
The third group, G3, despite being in the range that we have determined as 
general, corresponding to the majority of the population, also presents interesting 
differences. Among them, the works of Zhou et al. [85] and Kouidhi et al. [86] 
stand out. Their comparison between exposed subjects vs. controls found values 
corresponding to the median of 3.198 vs. 0.276 ng/ml serum in the first and 3.81 vs. 
0.73 ng/ml urine in the second. The same study line is the oldest academic article 
of the review, published by Hanaoka et al. in 2002 [87]. They determined very few 
differences between workers in the bisphenol diglycidyl ether (BADGE) industry 
vs. controls, with medians of 1.06 vs. 0.52 μmol/mol creat. Similarly, He et al. [88] 
determine few differences between exposed workers and their families, determin-
ing a GM of 1.41 ng/ml in exposed men, compared to 0.58 in their women or 0.78 
in their children under 20 years of age. Waldman et al. [89] and González et al. 
[90] also show low GM values. The first measures BPA’s urinary concentrations 
in firefighters, engineers, captains, or battalion commanders, determining a GM 
of 1.58 ng/ml. In the second, they determine BPA’s concentration in workers of an 
incinerator of hazardous waste, determining a GM of 0.68 in men and 1.2 ng/ml in 
women. Thayer et al. [91] and Lee et al. [92] carried out two publications focusing 
on cashiers exposed to thermal tickets. The first determines GM (SD) in pre-shift 
vs. post-shift cashiers of 1.89 (3.63) vs. 2.76 (3.53) μg/g creat., being 1.25 (1.79) in 
controls that do not work as cashiers. The second publication finds subtle differ-
ences only in those cashiers who do not wear gloves, observing GM values pre- vs. 
post-shift of 0.4 vs. 0.9 ng/ml in cashiers without gloves, and 0.44 vs. 0.49 ng/ml 
in tellers with gloves. Finally, it remains to mention the work of Hehn et al. [93], in 
which analyzing the data from the American health program NHANES according to 
Endocrine Disruptors
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the possible potential exposure. They determine GM values in women with prob-
able vs. unlikely exposure of 5.45 vs. 2.16 ng/ml, thus as of 2.85 vs. 2.59 ng/ml in 
men’s case.
6. Tolerable daily intake (TDI); calculations and extrapolations
Tolerable Daily Intake (TDI) is “the maximum amount of a contaminant which 
can be eaten every day over a whole lifetime without incurring appreciable risk 
to health” [94]. Currently, the European Food Safety Authority (EFSA) estimates 
it at 4 μg/kg BW/day [31]. The TDI calculated by EFSA is based on the studies of 
Tyl et al. [95], in which the concentration limit at which no adverse effects were 
observed, NOEL or NOAEL, was determined. They used concentrations from 0.03 
to 50 and 600 mg/kg BW/day (0.018–3500 ppm) in mice of different generations. 
They only observed renal effects (increase in organ weight) at the highest dose 
(600 mg/kg BW/day), thereby determining the NOEL at the next lower dose they 
used, which corresponds to 50 mg/kg BW/day. Thus, based on the renal NOEL/
NOAEL and due to the presumption of limitations in the use of the parameter, the 
EFSA calculates the equivalent “Benchmark dose” (BMD). The equivalent concen-
tration, in which it is estimated that there is an alteration in kidney weight in 10% 
of the treated animals, is 9 mg/kg. After applying a correction factor to estimate 
the equivalent dose in humans, a concentration of about 600 μg/kg is obtained. 
Finally, an uncertainty factor of 150 is applied to obtain the final result of 4 μg/kg 
BW/day [31].
To determine if the population is exposed to a high or low BPA concentration, 
the estimated daily intake (EDI) must finally be calculated. Exposure levels are 
expressed as a mass (nanograms or micrograms) per kg of weight per day. For this 
reason, it is necessary to multiply the urinary concentration of BPA in ng/ml by the 
average volume of urine (in ml) excreted per day and divide this number by the 
average weight measured in kilograms (reference values extracted from academic 
literature [96]). When taking the average value between adult men and women, a 
value of 1400 ml per day is obtained. The publication itself also shows the refer-
ence values for body weight, expressed in kg. When taking the same average as that 
applied to the urinary volume, adults’ average weight would correspond to a value 
of 66.5 kg. In this way, as reflected in Table 3, the main EDIs were calculated.
Statistical 
parameter
Population Value (ng/ml) μg/kg BW/day
GM General population [own work] 1.55 0.03
AM Conventional dialysis [80] 52.73 to 155.84 1.11 – 3.28
AM Online hemodiafiltration [80] 8.79 to 23.42 0.19 – 0.49
Median Occupational Exposure [89] 243.08 5.12
MAX Occupational Exposure [88] 268,975.33 5.662.64
P95 Pregnant woman [92] 250.06 5.26
P95 ICU patients [94] 113.7 2.39
Note that the maximum occupational exposure value reaches 5.66 mg/kg BW/day (1000 times higher than TDI). 
Abbreviations: GM, geometric mean; AM, arithmetic mean; MAX, maximum value; P95, 95th percentile.
Table 3. 
Most relevant values in the systematic review.
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7. Discussion
In the first place, an interesting element to consider resides in the pharmacoki-
netics models since they add modifications to BPA in order to determine it effi-
ciently and without contamination by HPLC. After the first model made by Volkel 
et al. [41], where they used d(16)-bisphenol A, successive authors have emulated 
this methodology in order to accurately measure the pharmacokinetics of adminis-
tered BPA [54, 55, 97–100]. However, deuterium modification of drugs is used today 
to reduce toxicity by redirecting metabolic pathways [101]. Perhaps the possibility 
that not all BPA is excreted in urine should be reconsidered with this in mind. We 
know that mice excrete BPA in feces; however, there are no publications in the 
literature that quantify BPA in human feces, although the presence of microplastics 
in them has recently been demonstrated [102].
Secondly, since it is described that BPA is a hydrophobic molecule, but with 
slight aqueous solubility and with the capacity to cross all types of biological tis-
sues [29, 41, 103], it is possible their bioaccumulation in the organism. To do this, 
Richard W. Stahlhut’s team determined BPA concentrations as a function of fasting 
time. Surprisingly, BPA levels did not decrease rapidly with fasting time, suggesting 
that there may be non-food exposure or bioaccumulation in body tissues [104].
Thirdly, another critical element is the possible non-monotonic effects of BPA 
on various organs and tissues [105–107]. This non-monotonicity can significantly 
affect at low concentrations, below the current TDI, in the same way that it has 
been shown to happen with certain hormonal stimuli. In her review, Vanderberg 
[105] determined that non-monotonic dose–response curves (NMDRCs) are typical 
in the literature related to BPA, occurring in greater than 20% of all experiments 
and at least one endpoint in more than 30% of all studies examined [105]. Going 
a little deeper into the non-monotonic effects works such as that of Angle et al. 
demonstrate the existence of multimodal dose–response curves [108]. Recent data 
suggest that the non-monotonic effect of BPA could depend upon the target tissue. 
In our studies in mice, we observed that while BPA induces hypertension in a dose-
dependent manner, it affects renal podocytes in a classical non-monotonic response 
curve [22, 23, 27]. In multimodal curves, increases and decreases are observed, and 
variations in the maximum response depending on the type of tissue [108] may 
further complicate the correct assessment of BPA’s presumed safety concentrations 
currently found in the population.
Throughout this chapter, an average urinary BPA value for the general popula-
tion has been determined using a systematic methodology to serve as a reference. 
Similarly, the analysis of the different statistical parameters shown in the publi-
cations determined population groups of special interest, such as workers with 
occupational exposure, pregnant women, or intensive care patients. With the 
latest discoveries in the BPA-nephro-vascular system paradigm, all this provides 
a sufficient basis to place kidney patients in the critical spotlight. The systematic 
review has determined relatively high BPA plasma values in patients undergoing 
hemodialysis, which could be a potentiating element for its worsening. In this way, 
the need to modify the materials used in specific treatments to reduce exposure 
to this endocrine disruptor is determined, thus avoiding some patients’ possible 
deterioration. Similarly, the high values of urinary BPA in various publications 
related to occupational exposure show the need to improve personal protective 
equipment and working conditions in specific sectors related to the manufacture 
or recycling of plastics, since concentrations should not be detected urinary 
levels high enough to reach the micromolar or even nanomolar range. Although 
we have indeed normalized the existence of endocrine disruptors in the general 
Endocrine Disruptors
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population’s urine, which is a worrying fact, we should ensure that they are at the 
lowest possible threshold.
EFSA determines that the TDI is at four μg/kg BW/day, which is justified with 
experimental animal models. However, as in vitro experiments have shown, BPA 
can exert very different actions in murine and human cells, although with similar 
consequences, converging on the possibility of kidney damage. It remains to be 
determined whether it would be necessary to review the coherence of the calcula-
tions and extrapolations, taking into account the observed inter-species differences.
8. Conclusions
• Novel data suggest that human exposure to bisphenol A is associated with 
renal, cardiovascular, and hypertensive diseases.
• The inter-species differences observed in the basic research models show inter-
esting evidence to rethink the institutions’ calculations that determine the TDI.
• The use of modified molecules in the pharmacokinetic models and the absence 
of studies in feces (and the presence of microplastics) suggest the possibility 
that not all BPA is excreted in the urine, which would mean that the concentra-
tions described would be below the actual exposure.
• The development of the systematic review using the premise of pharmaco-
kinetic studies shows a relatively low general exposure, but with population 
groups of interest, such as workers with occupational exposure and patients 
from the hospital environment.
• The data obtained and the novelties in basic research provide sufficient evi-
dence to consider the patient with kidney disease as one of the priority groups 
in which their exposure should be reduced, possibly by modifying the medical 
material’s composition.
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